Open-Label, Dose Escalation Early Phase 1 Study of ER2001 Intravenous Injection Repetitive Treatment in Adults With Early Manifest Huntington's Disease.
Latest Information Update: 23 Jan 2026
At a glance
- Drugs ER 2001 (Primary)
- Indications Huntington's disease
- Focus Adverse reactions
- Sponsors ExoRNA Bioscience
Most Recent Events
- 23 Jan 2026 New trial record